BEREKO PHARMA LIMITED

Company Registration Number:
12266152 (England and Wales)

Unaudited abridged accounts for the year ended 31 October 2023

Period of accounts

Start date: 01 November 2022

End date: 31 October 2023

BEREKO PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 31 October 2023

Company Information - 3
Balance sheet - 4
Additional notes - 6
Balance sheet notes - 9

BEREKO PHARMA LIMITED

Company Information

for the Period Ended 31 October 2023




Director: Mohamed Jalloh
Registered office: 16 Bell Terrace
Dartford
Kent
GBR
DA1 5FN
Company Registration Number: 12266152 (England and Wales)

BEREKO PHARMA LIMITED

Balance sheet

As at 31 October 2023


Notes

2023
£

2022
£
Fixed assets
Tangible assets: 4 6,743 7,932
Total fixed assets: 6,743 7,932
Current assets
Stocks: 679 847
Debtors: 1,438 503
Cash at bank and in hand: 337 563
Total current assets: 2,454 1,913
Creditors: amounts falling due within one year: ( 77,825 ) ( 60,321 )
Net current assets (liabilities): ( 75,371 ) ( 58,408 )
Total assets less current liabilities: ( 68,628 ) ( 50,476 )
Total net assets (liabilities): ( 68,628 ) ( 50,476 )

The notes form part of these financial statements

BEREKO PHARMA LIMITED

Balance sheet continued

As at 31 October 2023


Notes

2023
£

2022
£
Capital and reserves
Called up share capital: 1,000 1,000
Profit and loss account: ( 69,628 ) ( 51,476 )
Shareholders funds: ( 68,628 ) ( 50,476 )

For the year ending 31 October 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 4 March 2024
And Signed On Behalf Of The Board By:

Name: Mohamed Jalloh
Status: Director

The notes form part of these financial statements

BEREKO PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 October 2023

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover represents amounts receivable for services and goods and commission receivable excluding value added tax.

    Tangible fixed assets depreciation policy

    Depreciation is calculated so as to write off the cost of all fixed assets over their expected useful life.
    The rates applied are:-
    Furnitures, Fixtures & Equipment - 15% on written down value.

BEREKO PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 October 2023

  • 2. Employees


    2023

    2022
    Average number of employees during the period 0 0

BEREKO PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 October 2023

  • 3. Off balance sheet disclosure

    No

BEREKO PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 October 2023

4. Tangible Assets

Total
Cost £
At 01 November 2022 12,914
Additions -
Disposals -
Revaluations -
Transfers -
At 31 October 2023 12,914
Depreciation
At 01 November 2022 4,982
Charge for year 1,189
On disposals -
Other adjustments -
At 31 October 2023 6,171
Net book value
At 31 October 2023 6,743
At 31 October 2022 7,932